Skip to main content

Table 3 Characteristics of the patient group

From: Modeling patients’ time, travel, and monitoring costs in anticoagulation management: societal savings achievable with the shift from warfarin to direct oral anticoagulants

Variable

All geocoded patients (N = 6519)

Warfarin (N = 4560)

DOACs (N = 1239)

No medication (N = 720)

Age, mean (SD)

76.5 (10.5)

78.1 (9.4)

75.1 (10.1)

68.5 (13.5)

Retired, age ≥ 63 years, n (%)

5896 (90.5)

4302 (94.3)

1103 (89.0)

491 (68.2)

Gender, male, n (%)

3532 (54.2)

2388 (52.4)

663 (53.5)

481 (66.8)

BMI, mean (SD)

29.1 (6.2)

29.3 (6.4)

29.3 (5.8)

28.1 (5.4)

Obesity (BMI > 30), n (%)

1456 (22.3)

1006 (22.1)

327 (26.4)

123 (17.1)

CHA2DS2-VASc, mean (SD)a

3.1 (1.6)

3.3 (1.5)

3.1 (1.6)

1.9 (1.6)

Diabetes, n (%)

1648 (25.3)

1210 (26.5)

315 (25.4)

123 (17.1)

Hypertension, n (%)

3261 (50.0)

2302 (50.5)

696 (56.2)

263 (36.5)

Vascular disease, n (%)b

1657 (25.4)

1219 (26.7)

323 (26.1)

115 (16.0)

Congestive heart failure, n (%)

976 (15.0)

771 (16.9)

161 (13.0)

44 (6.1)

Transient ischemic attack (TIA), n (%)

271 (4.2)

188 (4.1)

73 (5.9)

10 (1.4)

Home address in assisted living building, n (%)

765 (11.7)

599 (13.1)

93 (7.5)

73 (10.1)

Number of INR measurements in 2017, mean (SD)

15.4 (11.0)

15.9 (10.9)

  

Standard TTR definable in 2017, n (%)

3524 (54.1)

3307 (72.5)

  
  1. aAnticoagulation medication should be used for patients having the score of 2 or more
  2. bVascular disease includes the following ICD-10 codes: I20-I25, I70.9